/Investor DB

Alpha Wave Global — 2024 Investments

7 investments dated 2024 · listed companies and verified rows first · show all

Mstackmstack.coOct 2024 · $40M✓ verified

Mstack builds an AI platform for chemical synthesis that reduces development timelines from 18+ months to days by learning reaction mechanisms and predicting optimal synthesis routes.

Advanced ManufacturingAI & Machine LearningDeep TechNew MaterialsSan Francisco, US

Co-investorsFormus CapitalLightspeed India PartnersLightspeed Venture Partners

Manus Biomanusbio.comin𝕏May 2024SEC filingmedium confidence

Manus Bio uses industrial biotechnology and engineered microbial cell factories to produce "BioAlternatives" — sustainable versions of molecules normally sourced from petrochemicals, agriculture, or animal husbandry — and offers a scale-up platform covering cell factory design through biomanufacturing.

BiotechFoodTechNew MaterialsAugusta, US

Aji Parayil(Co-founder)inGreg Stephanopoulos(Co-founder)

BoardJason Whaley(Director)inCarsten Boers(Director)inRichard Goldstein(Director)

Board seatRick Gerson· per SEC Form D · $11.3M raise · filed May 2024

Co-investors+ND CapitalAlumni VenturesCivilization Ventures Management, LlcEnergy Impact PartnersLiebenthal VenturesNelstone Ventures+4 more

HI-Biohibio.comJan 2024acquired by Biogen

Biotech company developing antibodies to treat autoimmune and inflammatory diseases.

Co-investorsArkin CapitalArkin Digital HealthJeito CapitalMonograph Capital PartnersViking GlobalARCH Venture Partners+1 more

Mareamareatx.comin𝕏Jun 2024

Acquired by Lisata Therapeutics alongside a $225 million concurrent private placement.

BiotechSan Francisco, US

Mark Joing(Executive Officer)inChristine Garrett(Executive Officer)inJosh Lehrer(Executive Officer, Director)inEthan Weiss(Executive Officer)inCaitlin Murray(Executive Officer)

BoardJeff Tong(Director)

Co-investorsSofinnova VenturesThird Rock VenturesvenBio PartnersForbion

Metserametsera.comin𝕏Nov 2024acquired by Pfizer

Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.

BiotechHealthtechMedical DevicesNew York, US

Clive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)Clive Meanwell(Founder)

Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalSoftBank Vision FundViking Global+5 more

Momosmomos.cominSep 2024 · $10M

Momos provides AI agents for hospitality brands that automate guest relations across channels such as reviews, SMS, email, and third-party delivery, auto-resolving support tickets and generating customer experience insights.

AI & Machine LearningMarketing TechSaaS

Sai Alluri(Founder)inAndrew Liu(Founder)in

Co-investors645 VenturesBrainstorm VenturesCaptii VenturesCorrelation VenturesFJ LabsHOF Capital+6 more

Zuddlzuddl.comin𝕏Series A · May 2024

Zuddl provides a unified platform for organizing and running webinars and events across virtual, hybrid, and in-person formats.

Enterprise SoftwareMarketing TechSaaSSan Francisco, US

Bharath Varma(Founder)inVedha Sayyaparaju(Founder)inKomal Baid(Technical Recruiter)Sahiba Ali(People Acquisition Specialist)Danny Miroyan(Vice President of Global Sales)Madhav Vamsi(Advisor)

Co-investorsMerak VenturesQualcomm VenturesY CombinatorDarkmode VenturesEveninggrowX Ventures+2 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.